Last updated: March 19, 2025
Sponsor: Cairo University
Overall Status: Active - Not Recruiting
Phase
3
Condition
Manic Disorders
Dementia
Williams Syndrome
Treatment
Gabapentin 400 mg capsules
Placebo
Gabapentin 600 mg capsules
Clinical Study ID
NCT06887998
gabapentin for agitation
Ages 18-60 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All patients (male/female, American Society of Anesthesiologists physical statusI-II, age: 18-60 years) undergoing elective nasal surgery will be eligible for thestudy.
Exclusion
Exclusion Criteria:
hypersensitivity to gabapentin
patient refusal
epilepsy
neurological or psychological conditions that impair communication.
current use of gabapentin, psychotropic or opioids medications.
Study Design
Total Participants: 63
Treatment Group(s): 3
Primary Treatment: Gabapentin 400 mg capsules
Phase: 3
Study Start date:
March 01, 2025
Estimated Completion Date:
March 31, 2026
Connect with a study center
Kasr Elainy Hospital , Cairo University
Cairo, 11956
EgyptSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.